Soluble Neprilysin, NT-proBNP, and Growth-Differentiation-Factor-15 as Biomarkers for Heart Failure in Dialysis Patients (SONGBIRD)

Hannover Medical School (MHH)

Status

Completed

Conditions

End Stage Renal Disease

Heart Failure

Treatments

Diagnostic Test: Diagnostic biomarker study

Study type

Observational

Funder types

Other

Identifiers

NCT04061811

7952_BO_S_2018

KlinStrucMed program (Other Grant/Funding Number)

Details and patient eligibility

About

Objectives: The aim of this study is to determine whether growth differentiation factor-15 (GDF15) and circulating neprilysin (cNEP) improve the diagnosis of congestive heart failure (HF) in patients on dialysis.

Background: Dialysis patients are at increased risk of HF. However, diagnostic utility of NT-proBNP as a biomarker is decreased in patients on dialysis. GDF15 and cNEP are biomarkers of distinct mechanisms that may contribute to HF pathophysiology in such cohorts.

Methods: We compare circulating concentrations of NT-proBNP, GDF15, and cNEP along with NEP activity in patients on chronic dialysis without and with HF, as diagnosed by clinical parameters and post-dialysis echocardiography. We use correlation, linear and logistic regression as well as receiver operating characteristic (ROC) analyses.

Enrollment

153 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

ESRD on either chronic hemodialysis (HD) or peritoneal dialysis (PD) for ≥3 months

Exclusion criteria

previous switch of the type of renal replacement therapy from HD to PD or vice versa
age <18 years
pregnancy
plasma exchange or apheresis in the past 6 months
unipolar pacemaker
history of whole extremity amputation